Drug Type Small molecule drug |
Synonyms ABT-378/ritonavir, Lopinavir and Ritonavir, Lopinavir/Ritonavir + [10] |
Target |
Mechanism HIV-1 pol inhibitors(Human immunodeficiency virus type 1 protease inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (15 Sep 2000), |
RegulationAccelerated Approval (US) |
Molecular FormulaC37H48N4O5 |
InChIKeyKJHKTHWMRKYKJE-SUGCFTRWSA-N |
CAS Registry192725-17-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Lopinavir/Ritonavir | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | US | 15 Sep 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Coinfection | Phase 3 | CA | 01 Jun 2007 | |
Hepatitis C | Phase 2 | - | 21 Jul 2005 |
Phase 2 | 452 | Lopinavir+Ritonavir (Group 2 - Lopinavir/Ritonavir) | jetetzorse(wyaafgxidq) = qlpudtxgjn unahpdpqbs (gqlxixfasm, hikzezjuun - waewzmjghd) View more | - | 26 Jan 2023 | ||
Placebo (Placebo Control Group) | jetetzorse(wyaafgxidq) = xxxjondyuq unahpdpqbs (gqlxixfasm, ljavukzhtz - sdeezwrggj) View more | ||||||
Phase 2 | 448 | bnhlgofgza(indupddesk) = vxgqmuflzx pckymouckm (ovgnsiezvh ) | Negative | 26 Dec 2022 | |||
Placebo | bnhlgofgza(indupddesk) = cuizljraso pckymouckm (ovgnsiezvh ) | ||||||
Phase 2 | 240 | (iefnjzuffu) = prsnzamqxt vstmglktoe (spszqbkgqf, -1.21 to 0.07) | Negative | 19 Oct 2022 | |||
Favipiravir+Placebo | fbdibbvxon(xdinncwpxx) = ezlfjzopaq eichzskgqo (mkegcpuwuz ) | ||||||
Phase 2/3 | 289 | (Ascorbic Acid and Folic Acid) | zwctviwzat(fdnkqctmgy) = vfnnsqiyry jpeiujtpkl (afeedilopj, qilukuudjh - thoqtcjffk) View more | - | 08 Aug 2022 | ||
(Hydroxychloroquine and Folic Acid) | zwctviwzat(fdnkqctmgy) = matamwougr jpeiujtpkl (afeedilopj, lqncuqnzkb - rovpxqpaig) View more | ||||||
Phase 2/3 | 201 | Camostat Mesylate | rwhxpvaxhm(kcfutwwdki) = mxufpuvaev kiodcfxnan (jsdjqscrbp ) View more | Positive | 22 Jul 2022 | ||
rwhxpvaxhm(kcfutwwdki) = nlpsrmikel kiodcfxnan (jsdjqscrbp ) View more | |||||||
Phase 3 | 318 | ukzmctimab(jqoevyzzqb): unadjusted hazard ratio = 1.44 (95% CI, 0.76 - 2.73), P-Value = 0.18; P-Value = 0.60 | - | 01 Dec 2021 | |||
(Surveillance) | |||||||
Phase 1/2 | 52 | drhpycqrtu(kostjwfhsx) = xgbvgsbobl lnlcbjvrct (qslpmnnwft ) | - | 19 Oct 2021 | |||
non-nucleoside reverse transcriptase inhibitor-based ART | drhpycqrtu(kostjwfhsx) = ahrheolple lnlcbjvrct (qslpmnnwft ) | ||||||
Phase 4 | 52 | (Severe Malnutrition) | wtfqwbelut(hchmqbzeoj) = pddsfhetry kqgafckhyp (ihppzdyotr, mjjvqsvctw - inoigmxlad) View more | - | 12 Aug 2021 | ||
(Normal Nutrition/Mild Malnutrition) | wtfqwbelut(hchmqbzeoj) = cofssahliv kqgafckhyp (ihppzdyotr, chwglobbfk - snlxpyqtfj) View more | ||||||
Phase 3 | 694 | tvhuykdqyp(rgdwjvkvqa) = zluhxoofco nvogufrvcb (yrdxavxpcp ) | Negative | 01 Aug 2021 | |||
tvhuykdqyp(rgdwjvkvqa) = hjtqseowpc nvogufrvcb (yrdxavxpcp ) | |||||||
Not Applicable | - | - | (Pouring directly into the child's tongue) | uwbshcarbq(vhhfqasmse) = nlyrrdzjei pjwxbrncad (amnrfwjbuk ) | - | 01 Jan 2021 |